372 related articles for article (PubMed ID: 25669970)
1. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
2. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.
Bruyer A; Maes K; Herviou L; Kassambara A; Seckinger A; Cartron G; Rème T; Robert N; Requirand G; Boireau S; Müller-Tidow C; Veyrune JL; Vincent L; Bouhya S; Goldschmidt H; Vanderkerken K; Hose D; Klein B; De Bruyne E; Moreaux J
Br J Cancer; 2018 Apr; 118(8):1062-1073. PubMed ID: 29500406
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
[TBL] [Abstract][Full Text] [Related]
4. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
5. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modulators as therapeutic targets in prostate cancer.
Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
[TBL] [Abstract][Full Text] [Related]
7. DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo.
Yi TZ; Li J; Han X; Guo J; Qu Q; Guo L; Sun HD; Tan WH
Chemotherapy; 2012; 58(1):19-29. PubMed ID: 22343305
[TBL] [Abstract][Full Text] [Related]
8. [The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma].
Terui Y
Nihon Rinsho; 2015 Jan; 73(1):124-9. PubMed ID: 25626317
[TBL] [Abstract][Full Text] [Related]
9. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
10. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
11. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
Rondelet G; Wouters J
Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
13. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.
Moreaux J; Rème T; Leonard W; Veyrune JL; Requirand G; Goldschmidt H; Hose D; Klein B
Mol Cancer Ther; 2012 Dec; 11(12):2685-92. PubMed ID: 23087257
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Moreno-Bost A; Szmania S; Stone K; Garg T; Hoerring A; Szymonifka J; Shaughnessy J; Barlogie B; Prentice HG; van Rhee F
Cytotherapy; 2011 May; 13(5):618-28. PubMed ID: 21171821
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Pera B; Tang T; Marullo R; Yang SN; Ahn H; Patel J; Elstrom R; Ruan J; Furman R; Leonard J; Cerchietti L; Martin P
Clin Epigenetics; 2016; 8():79. PubMed ID: 27453763
[TBL] [Abstract][Full Text] [Related]
16. The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.
Maes K; De Smedt E; Lemaire M; De Raeve H; Menu E; Van Valckenborgh E; McClue S; Vanderkerken K; De Bruyne E
Oncotarget; 2014 May; 5(10):3115-29. PubMed ID: 24833108
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.
Aouali N; Broukou A; Bosseler M; Keunen O; Schlesser V; Janji B; Palissot V; Stordeur P; Berchem G
PLoS One; 2015; 10(6):e0130339. PubMed ID: 26091518
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
20. A selective activity of DNMTi decitabine on AML1ETO positive cells?
Santini V
Leuk Res; 2007 Jun; 31(6):741-2. PubMed ID: 17240447
[No Abstract] [Full Text] [Related]
[Next] [New Search]